Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy
Source : https://www.sciencedirect.com/science/article/abs/pii/S0735109723064689?via=ihub
The frequency, characteristics and outcomes of patients treated with high-intensity lipid-lowering therapy and showing concomitant atheroma volume red...
Conclusions: Triple regression occurred in one third of AMI patients receiving high-intensity lipid-lowering therapy and was associated with alirocumab treatment, higher baseline lipid content and reduced cardiovascular events.
Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37612600/
Statins did not increase the risk of pregnancy-related AEs, including abortion, abortion spontaneous, or stillbirth/fetal death. However, we did find significant disproportionality signals for preterm birth and low birth weight...
Conclusions: Statins did not increase the risk of pregnancy-related AEs, including abortion, abortion spontaneous, or stillbirth/fetal death. However, we did find significant disproportionality signals for preterm birth and low birth weight associated with pravastatin, and lovastatin was related to a higher proportion of fetal complications....
Meaning: The observed safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics of muvalaplin in healthy participants support further clinical evaluation in patients with elevated Lp(a) levels.
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study - American Journal of Cardiovascular Drugs
Source : https://link.springer.com/article/10.1007/s40256-023-00604-6
Introduction The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the...
Conclusion: We did not find effect of monoclonal antibody PCSK9i on neurocognitive function over 24 months of treatment, either in global MoCA score or different cognitive domains. An improvement in delayed recall memory was shown. The study showed no differences in the cognitive function between the prespecified subgroups, even among...
Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37623860/
It has been consistently demonstrated that circulating lipids and particularly low-density lipoprotein cholesterol (LDL-C) play a significant role in the development of coronary artery disease (CAD). Several trials have been...
Conclusions/Relevance: This review aims to discuss the possible lipid-lowering strategies in post-ACS and to identify those patients who might benefit most from more powerful treatments and up-to-date management.
